TG THERAPEUTICS, INC. TGTX

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. We also actively evaluate complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Last close 54.17 2026-10-23
Market cap $8.29B 2026-06-30 share count
52-week range 26.76 - 59.30

Valuation FY2025 figures against the last close

P/S13.5x
P/E19.6x
P/FCF—
EV/EBITDA68.0x
Dividend yield—
Diluted EPS2.77

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $616.3M$329.0M$233.7M$2.8M$6.7M$152.0K$152.0K$152.0K$152.0K$152.0K
Cost of revenue $100.7M$38.5M$14.1M$265.0K$790.0K—————
Gross profit $515.6M$290.5M$219.5M$2.5M$5.9M—————
R&D $160.2M$94.3M$76.2M$125.4M$222.6M$165.9M$154.2M$159.4M$102.5M$69.2M
SG&A $232.0M$154.3M$122.7M$95.5M$128.1M$107.8M$15.0M$15.2M$16.3M$9.9M
Total operating expenses $493.0M$287.1M$213.0M$221.1M$351.5M$273.7M$169.2M$174.6M$118.9M$79.1M
Operating income $123.3M$41.9M$20.6M-$218.3M-$344.8M-$273.6M-$169.1M-$174.4M-$118.7M-$79.0M
Interest expense $26.7M$24.0M$12.6M$10.2M$5.6M$6.3M$5.3M$877.0K$845.0K—
Pre-tax income $107.4M$25.6M$13.1M-$223.8M-$348.1M-$279.4K-$172.9K-$173.5K-$118.5K-$78.3M
Income tax $339.8M$2.2M$390.0K$0$0$0$0$0$0$0
Net income $447.2M$23.4M$12.7M-$198.3M-$348.1M-$279.4M-$172.9M-$173.5M-$118.5M-$78.3M
EPS, basic 3.100.160.09-1.65-2.63-2.42————
EPS, diluted 2.770.150.09-1.65-2.63-2.42-1.96-2.30-1.91-1.60
Shares, diluted (wtd. avg.) 161.4M160.3M148.5M135.4M132.2M115.3M————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $79.1M$179.9M$92.9M$102.3M$298.9M$553.4M$113.9M$43.2M$57.3M$25.6M
Short-term investments $62.8M$131.1M$124.6M$59.4M$15.9M$52.0M$27.8M$26.9M$28.0M$19.9M
Receivables $305.6M$129.2M$51.1M$0$1.4M—————
Inventory $125.6M$110.5M$39.8M$0——————
Total current assets $630.8M$566.4M$317.9M$168.3M$331.0M$611.7M$149.2M$79.0M$93.3M$50.9M
Property, plant and equipment ——$95.0K$307.0K$600.0K$481.0K$282.0K$251.0K$248.0K$328.1K
Goodwill ——$799.0K$799.0K$799.0K$799.0K$799.0K$799.0K$799.0K$799.4K
Total assets $1.06B$577.7M$329.6M$193.6M$379.6M$625.6M$163.0M$83.6M$97.4M$54.8M
Accounts payable $107.5M$58.3M$38.5M$42.0M$51.3M$37.0M$30.0M$36.4M$25.9M$15.3M
Short-term debt ———$0$975.0K$22.2M$0———
Total current liabilities $153.8M$90.7M$53.7M$53.2M$65.4M$87.6M$84.4M$38.9M$28.0M$16.9M
Long-term debt $245.6M$244.4M$100.1M$71.1M$66.8M$7.7M$29.0M$0——
Total liabilities $415.2M$355.3M$169.1M$135.0M$142.5M$106.3M$124.4M$59.6M$30.4M$18.9M
Retained earnings -$1.08B-$1.53B-$1.55B-$1.53B-$1.33B-$980.6M-$701.2M-$528.3M-$354.9M-$236.4M
Total equity $648.0M$222.4M$160.5M$58.6M$237.2M$519.4M$38.6M$24.0M$67.0M$35.9M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$24.8M-$40.5M-$31.4M-$176.2M-$295.6M-$214.5M-$132.8M-$128.9M-$93.8M-$61.6M
Depreciation and amortisation $59.0K$68.0K$211.0K$303.0K$282.0K$158.0K$100.0K$88.0K$82.0K$63.0K
Stock-based compensation $64.7M$42.5M$37.9M$44.7M$61.3M$80.3M$11.3M$12.9M$15.9M$7.5M
Capital expenditure $214.0K$45.0K$0$14.0K$401.0K$357.0K$131.0K$90.0K$2.0K$344.0K
Investing cash flow $13.8M-$1.0M-$50.7M-$20.0M-$332.0K-$24.5M-$718.0K$1.2M-$8.2M$26.5M
Financing cash flow -$89.7M$128.5M$72.7M-$391.0K$41.4M$679.8M$204.2M$113.6M$133.7M$5.0M
Buybacks $91.2M$8.8M————————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-014233.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -500M -250M 0 250M 500M 750M Revenue, FY2016: 152K Net income, FY2016: -78.3M Revenue, FY2017: 152K Net income, FY2017: -118.5M Revenue, FY2018: 152K Net income, FY2018: -173.5M Revenue, FY2019: 152K Net income, FY2019: -172.9M Revenue, FY2020: 152K Net income, FY2020: -279.4M Revenue, FY2021: 6.7M Gross profit, FY2021: 5.9M Net income, FY2021: -348.1M Revenue, FY2022: 2.8M Gross profit, FY2022: 2.5M Net income, FY2022: -198.3M Revenue, FY2023: 233.7M Gross profit, FY2023: 219.5M Net income, FY2023: 12.7M Revenue, FY2024: 329M Gross profit, FY2024: 290.5M Net income, FY2024: 23.4M Revenue, FY2025: 616.3M Gross profit, FY2025: 515.6M Net income, FY2025: 447.2M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $152.0K $152.0K $152.0K $152.0K $152.0K $6.7M $2.8M $233.7M $329.0M $616.3M
Gross profit — — — — — $5.9M $2.5M $219.5M $290.5M $515.6M
Net income -$78.3M -$118.5M -$173.5M -$172.9M -$279.4M -$348.1M -$198.3M $12.7M $23.4M $447.2M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%